FDA
-
healthTrump's Psychedelics Order: Symbolic Gesture or a Real Shift?
Analysts weigh in on former President Trump's executive order aimed at accelerating psychedelic treatments for mental illness, questioning its practical impact versus symbolic value.
-
healthFDA Approves Groundbreaking Gene Therapy for Genetic Hearing Loss
The FDA has approved Otarmeni, the first gene therapy to treat severe to profound hearing loss linked to the OTOF gene, offering new hope for patients.
-
healthFDA Approves First Gene Therapy for Inherited Deafness
Regeneron's Otarmeni receives FDA approval, marking a significant advancement in treating OTOF gene-related hearing loss in children and adults.
-
healthTrump's Psychedelic Therapy Push: What You Need to Know
President Trump signs an executive order to fast-track research and FDA approval for psychedelic therapies, sparking debate on mental health treatment and patient safety.
-
healthTrump Accelerates Research on Psychedelic Drugs for Mental Health
President Trump signs an executive order to fast-track research into psychedelic drugs like psilocybin and ibogaine for treating mental health conditions, particularly in veterans.
-
healthTrump Greenlights Expedited Access to Psychedelic Drug Treatments
President Trump signs an executive order fast-tracking FDA review for psychedelic drugs like ibogaine, allocating $50 million for federal research into potential PTSD and substance abuse treatments.
-
healthTrump Accelerates Access to Psychedelic Drug Treatments
President Trump signs executive order to expedite research and treatment access for psychedelic drugs like ibogaine, particularly for veterans.
-
healthVeteran Leads Psilocybin Retreats for PTSD Ahead of FDA Approval
Army veteran Jesse Gould offers psilocybin retreats for PTSD, aiming to provide an alternative to lifelong medication while states explore therapeutic legalization.